109
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

, &
Pages 1073-1077 | Published online: 09 Aug 2013

References

  • [No authors listed]Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative GroupLancet19983529309429752815
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
  • FergusonTWilckenNVaggRGhersiDNowakAKTaxanes for adjuvant treatment of early breast cancerCochrane Database Syst Rev20074CD00442117943815
  • De LaurentiisMCancelloGD’AgostinoDTaxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trialsJ Clin Oncol200826445318165639
  • HopwoodPRidolfiARussellSImpact on quality of life (QoL) of FEC-T compared with FEC or CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-upJ Clin Oncol200826Suppl: abstr 548
  • RochéHFumoleauPSpielmannMSequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 TrialJ Clin Oncol2006245664567117116941
  • MartinMMackeyJVogelCBenefit from adjuvant taxanes and endocrine responsiveness in breast cancerBreast200716Suppl 2S127S13117923408
  • AndreFBroglioKRocheHEstrogen receptor expression and efficacy of docetaxel containing adjuvant chemotherapy in patients with node positive breast cancer: results from a pooled analysisJ Clin Oncol2008262636264318509176
  • HughJHansonJCheangMCBreast cancer subtypes and response to docetaxel in node-positive breast cancer use of an immunohistochemical definition in the BCIRG 001 TrialJ Clin Oncol2009271168117619204205
  • HayesDFThorADDresslerLGCancer and Leukemia Group B (CALGB) InvestigatorsHER2 and response to paclitaxel in node-positive breast cancerN Engl J Med20073571496150617928597
  • Cancer Therapy Evaluation ProgramCommon terminology criteria for adverse events 3.0 (CTCAE)2006 Available from: http://www.eortc.be/services/doc/ctc/ctcaev3.pdfAccessed February 28, 2013
  • HendersonICBerryDADemetriGDImproved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerJ Clin Oncol20032197698312637460
  • MamounasEPBryantJLemberskyBPaclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28J Clin Oncol2005233686369615897552
  • MartinMPienkowskiTMackeyJBreast Cancer International Research Group 001 InvestigatorsAdjuvant docetaxel for node-positive breast cancerN Engl J Med20053522302231315930421
  • BriaENisticoCCupponeFBenefits of taxane as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patientsCancer2006106112337234416649217